45 An integrative immune signature of complementary circulating and tumoral biomarkers maximizes the predictive power of adjuvant immunotherapeutic benefits for high-risk melanoma

Similar Items

• Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males
  by: Mariam Saad, et al.
  Published: (2022-06-01)
• Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary
  by: Lisa H Butterfield, et al.
  Published: (2022-01-01)
• CytoConverter: a web-based tool to convert karyotypes to genomic coordinates
  by: Janet Wang, et al.
  Published: (2019-09-01)
• Intracardiac leiomyomatosis: Report of two cases
  by: Pradeep Vaideeswar, et al.
  Published: (2011-01-01)
• Expression profiles of immune-related genes are associated with neoadjuvant ipilimumab clinical benefit
  by: Ahmad A. Tarhini, et al.
  Published: (2017-02-01)